Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether treatment with Bismuth can reduce the toxicity of chemotherapy and radiotherapy in patients with malignant diseases of the blood.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Copenhagen University Hospital at Herlev
NCT02269592 · Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, and more
NCT07472972 · Lymphoma, Lymphoid Hematological Malignancies
NCT07122674 · Hematological Malignancies
NCT06281496 · Hematological Diseases
NCT03802773 · Cord Blood Transplantation, Hematological Malignancies
Department of Haematology L, Herlev Hospital, Herlev Ringvej 75
Herlev
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions